ELOXX PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$326.20 thousand for the 12-month period ending 2013-06-30, per its 10-K filed 2013-09-11.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2013-09-11
- ELOXX PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2013-06-30 was -$54.37K, a 117.63% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2013-03-31 was -$227.54K.
- ELOXX PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2012-12-31 was -$64.44K, a 263.59% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2012-09-30 was $20.15K.
- ELOXX PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2013 was -$326.20K.
- ELOXX PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2012 was $0.00.
- ELOXX PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2011 was -$609.24K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month as first filed |
|---|---|---|---|---|---|
| 2013-06-30 | -$54.37K derived: 10-K 12 month − 10-Q 9 month · filed 2013-09-11 | -$281.91K derived: sum of 2 quarters · filed 2013-09-11 | -$346.35K derived: sum of 3 quarters · filed 2013-09-11 | -$326.20K 10-K · filed 2013-09-11 | |
| 2013-03-31 | -$227.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-05-15 | -$291.98K derived: sum of 2 quarters · filed 2013-05-15 | -$271.83K 10-Q · filed 2013-05-15 | $36.53K derived: sum of 4 quarters · filed 2013-09-11 | |
| 2012-12-31 | -$64.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-02-14 | -$44.29K 10-Q · filed 2013-02-14 | $264.07K derived: sum of 3 quarters · filed 2013-09-11 | $188.02K derived: sum of 4 quarters · filed 2013-09-11 | |
| 2012-09-30 | $20.15K 10-Q · filed 2012-11-14 | $328.51K derived: sum of 2 quarters · filed 2013-09-11 | $252.46K derived: sum of 3 quarters · filed 2013-09-11 | $291.85K derived: sum of 4 quarters · filed 2013-09-11 | |
| 2012-06-30 | $308.36K derived: 10-K 12 month − 10-Q 9 month · filed 2013-09-11 | $232.31K derived: sum of 2 quarters · filed 2013-09-11 | $271.70K derived: sum of 3 quarters · filed 2013-09-11 | $0.00 10-K · filed 2013-09-11 | -$472.46K 10-K/A · filed 2012-10-26 |
| 2012-03-31 | -$76.05K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-05-15 | -$36.66K derived: sum of 2 quarters · filed 2013-05-15 | -$308.36K 10-Q · filed 2013-05-15 | ||
| 2011-12-31 | $39.39K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-02-14 | -$232.31K 10-Q · filed 2013-02-14 | |||
| 2011-09-30 | -$271.70K 10-Q · filed 2012-11-14 | ||||
| 2011-06-30 | -$609.24K 10-K/A · filed 2012-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |